Physician profile
Henry Ramirez
NPI 1457534729
$6,938.19
in general payments reported to CMS, 2019-2025
30 companies · $73.24 in 2025
The $73.24 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $1,178 · 2021: $4,729 · 2022: $172 · 2023: $291 · 2024: $72.11 · 2025: $73.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $337 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $336.83 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,426.87 | 2019-2021 | |
| Celularity INC. | $949.99 | 2020 | |
| Mayne Pharma Commercial LLC | $330.18 | 2021-2024 | |
| Abbvie INC. | $283.97 | 2019-2023 | |
| Astellas Pharma US INC | $168.40 | 2021-2023 | |
| Therapeuticsmd, INC. | $86.11 | 2019-2021 | |
| Virtus Pharmaceuticals LLC | $81.87 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $75.25 | 2019-2021 | |
| Hologic Sales and Service, LLC | $54.02 | 2019-2025 | Myosure Tissue Removal Device |
| Exact Sciences Corporation | $49.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $44.83 | 2021 | |
| Novo Nordisk INC | $44.45 | 2019-2022 | |
| Acelrx Pharmaceuticals, INC. | $42.01 | 2021 | |
| Azurity Pharmaceuticals, INC. | $31.86 | 2023 | Adthyza |
| Vertex Pharmaceuticals Incorporated | $30.58 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $29.78 | 2019 | |
| Avanos Medical | $21.73 | 2019 | |
| Roche Diagnostics Corporation | $20.79 | 2019 | |
| Scynexis, INC. | $20.69 | 2022 | |
| Evofem Biosciences, INC. | $16.04 | 2021 | |
| Medtronic, INC. | $16.04 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.72 | 2019 | |
| Allergan, INC. | $14.34 | 2019 | |
| Pfizer INC. | $14.04 | 2021 | |
| Lilly USA, LLC | $13.12 | 2020 | |
| Covidien Lp | $12.67 | 2019 | |
| Janssen Biotech, INC. | $12.64 | 2019 | |
| Organon LLC | $11.98 | 2022 | |
| Amag Pharmaceuticals, INC. | $11.76 | 2019 | |
| Boston Scientific Corporation | $7.90 | 2025 | Bulkamid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.